Amgen Inc. with ticker code (AMGN) have now 23 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $336.00 and $185.00 suggesting an average Analsyt target price of $277.83. Given that the stocks previous close was at $270.87 this would imply there is now a potential upside of 2.6%. There is a 50 day moving average of $270.29 and the 200 moving average now moves to $246.85. The company has a market cap of 144.15B. The stock price is currently at: $269.35 USD
The potential market cap would be $147,854,137,243 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 19.16, revenue per share of $50.16 and a 7.86% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
